Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Factors Affecting Soluble Mesothelin Related Protein Levels In An Asbestos-exposed Population

Eun-Kee Park, P. Thomas, J. Creaney, A. Johnson, B. Robinson, D. Yates
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Abstract Background: Soluble mesothelin-related protein (SMRP) is increased in the sera of patients with malignant mesothelioma (MM), and has been suggested as a diagnostic tool for MM in an asbestos exposed population. However, factors affecting SMRP concentrations in normal subjects and those with other asbestos related disorders have not been investigated in any large population based study. Methods: Five hundred and thirty-eight subjects with a history of asbestos exposure were studied. Age, height, weight, body mass index (BMI), serum creatinine and glucose, estimated glomerular filtration rate (eGFR) and lung function were compared with SMRP concentrations. Results: The mean age [± standard deviation (SD)] of participants was 66.9 (±10.1) years, and mean (±SD) serum SMRP concentration was 0.91 (±0.67) nmol/L. SMRP values were inversely associated with weight (Pearson r=–0.1254, p=0.0036), BMI (Pearson r=–0.1594, p=0.0002), blood glucose (Pearson r=–0.1515, p=0.0004), single-breath carbon monoxide diffusing capacity (DLco) % predicted (Pearson r=–0.1847, p<0.0001), eGFR (Pearson r=–0.2835, p<0.0001) and single-breath carbon monoxide diffusing capacity per unit alveolar volume (DLco/VA)% predicted (Pearson r=–0.1872, p<0.0001) but were positively associated with age (Pearson r=0.2315, p<0.0001) and creatinine (Pearson r=0.3833, p<0.0001). Conclusions: This study has shown that demographic variables, physiological factors and lung function are associated with serum SMRP concentrations. Confounding factors should be considered when interpreting serum SMRP. Clin Chem Lab Med 2010;48:869–74.
This paper references
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
F. di Serio (2007)
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.
J. Cotes (1993)
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
Derlis Martino (2004)
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain.
A. Agudo (2000)
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
Occupational exposure to asbestos in New South Wales, Australia (1970–1989): development of an asbestos task exposure matrix
Rebecca A Hyland (2010)
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
Rebecca A Hyland (2007)
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin‐related protein and positron emission tomography
E. O'Lone (2009)
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
Standardization of Spirometry, 1994 Update. American Thoracic Society.
C. Irvin (1995)
Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.
D. Howel (1999)
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
Fujirebio Mesomark Assay. Humanitarian Device Exemption Number H060004, Document number 07M-0038
US FDA (2007)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
Standardization of the measurement of transfer factor (diffusing capacity)
J. Cotes (1993)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Fujirebio Mesomark Assay. Humanitarian Device Exemption Number H060004, Document number 07M-0038
US FDA (2007)
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
Single breath carbon monoxide diffusing capacity (transfer factor)
D. Johns (1988)
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Biomarkers for mesothelioma
A. Scherpereel (2007)
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)

This paper is referenced by
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
M. K. Felten (2013)
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.
Clementina A. Mesaros (2015)
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.
K. Hollevoet (2012)
Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population
G. Aguilar‐Madrid (2018)
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure.
K. Vyskočilová (2015)
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals
C. De Santi (2017)
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma
J. Creaney (2010)
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population
M. Yu (2015)
Malignant-Primary (MAL-P) (Mesothelioma)
C. W. Michael (2020)
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
P. Jakubec (2015)
Two Novel Polymorphisms in 5' Flanking Region of the Mesothelin Gene are Associated with Soluble Mesothelin-Related Peptide (SMRP) Levels
A. Cristaudo (2011)
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
Chapter 12 Biomarkers of Response to Asbestos Exposure
Blair ()
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
Association of Biomarker Levels with Severity of Asbestos-Related Diseases
E. Park (2012)
The International System for Serous Fluid Cytopathology
A. Chandra (2020)
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
H. Pass (2020)
Semantic Scholar Logo Some data provided by SemanticScholar